 | |
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H14N2O |
| Molar mass | 274.323 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
QH-II-66[1] (QH-ii-066) is asedative drug which is abenzodiazepine derivative.[2] It produces some of the same effects as other benzodiazepines, but is much more selective than most other drugs of this class and so produces somewhat less sedation andataxia than other related drugs such asdiazepam andtriazolam, although it still retainsanticonvulsant effects.[3]
QH-ii-066 is a highly subtype-selectiveGABAAagonist which was designed to bind selectively to theα5 subtype of GABAA receptors.[4]
The α5 subtype (and to a lesser extent the α1 subtype) of GABAA are two of the most important targets in the brain that produce the effects ofalcohol,[5] and so one of the purposes for which QH-ii-066 was developed was to reproduce theGABAergic effects of alcohol separately from its other actions.[6]
QH-ii-066 replicates some of the effects of alcohol, such as sedation and ataxia, but does not increase appetite, as this effect seems to be produced by the α1 subtype of GABAA rather than α5.[7] Theinverse agonistRo15-4513, which blocks the α5 subtype of GABAA, reverses the effects of alcohol, suggesting that this subtype is also important in producing the subjective effects of alcohol intoxication.[8]
